Juvisé Founder Ascends to Chairman, Heralding M&A-Driven Expansion

PARIS, France – April 16, 2026 – Juvisé Pharmaceuticals is embarking on a pivotal new chapter, signaling a strategic shift toward aggressive growth and global expansion. In a significant leadership restructuring announced yesterday, the company’s founder and long-time CEO, Frédéric Mascha, will transition to the roles of Executive Chairman and Chairman of the Supervisory Committee. Taking the operational helm as the new Chief Executive Officer, effective July 1, 2026, will be Renaud Sermondade, a seasoned executive with a deep background in the international pharmaceutical industry.

This calculated evolution in governance is more than a simple changing of the guard. It represents a deliberate strategy to blend the founder's entrepreneurial vision with seasoned operational expertise, all powered by a newly secured financial war chest dedicated to mergers and acquisitions. The move positions the Paris-based firm to accelerate its unique business model of acquiring and revitalizing essential medicines on a global scale.

A Founder's Strategic Pivot to M&A

Since founding Juvisé Pharmaceuticals in 2008, Frédéric Mascha has been the driving force behind its growth from a startup to a recognized international player with medicines marketed in over 80 countries. As CEO and majority shareholder, he pioneered a successful strategy of acquiring established, high-value therapeutic products that larger pharmaceutical giants had deprioritized. This approach not only built a robust portfolio in neurology, gastroenterology, and oncology but also ensured continued patient access to critical treatments.

Under his leadership, the company’s M&A department effectively became its engine of innovation, replacing traditional R&D with a focus on strategic acquisitions. Mascha’s deep experience, honed during his time as an Associate Principal at McKinsey & Company where he crafted launch strategies for major pharma companies, has been central to Juvisé's success.

In his new capacity as Executive Chairman, Mascha will step back from day-to-day operations to concentrate on the company's long-term strategic direction. His primary focus will be on steering global M&A activities and corporate finance—the very areas that have defined Juvisé’s growth to date. This transition allows the company to retain its founder’s deal-making acumen and strategic oversight while empowering a new leader to scale its global operations.

An International Expert to Steer Global Growth

To execute this ambitious expansion, the board has appointed Renaud Sermondade, 48, as the new CEO. Sermondade joins Juvisé with a formidable track record forged in senior leadership positions at some of the industry's most prominent companies, including Aptar Group, Sanofi, MSD, and Bristol Myers Squibb.

His career is marked by extensive international experience, having held key roles in China, the United States, and across Europe. Most recently, as President of the Aptar Injectables division, he demonstrated a keen ability to drive innovation and manage large-scale operations. His background is notably comprehensive, spanning sales, marketing, finance, strategy, business development, and R&D. Furthermore, his proven expertise in managing P&L responsibilities exceeding one billion euros across both mature and emerging markets makes him uniquely qualified to lead Juvisé’s next phase.

Sermondade’s appointment is a clear signal of Juvisé’s intent to deepen its international footprint. His experience in diverse and multicultural environments, combined with his leadership roles within organizations like the French pharmaceutical cluster Polepharma, equips him to navigate the complexities of global market access and commercial excellence. His mandate will be to build upon the strong foundation laid by Mascha, professionalizing the company’s structure to support a more aggressive and geographically diverse growth trajectory.

Fueling the Acquisition Engine

This leadership evolution is underpinned by a significant enhancement of Juvisé's financial firepower. In early 2026, the company secured a landmark €550 million refinancing package from Hayfin Capital Management, a British investment firm specializing in healthcare. This transaction was structured not only to repay existing debt but also to explicitly fund future growth.

Crucially, the package includes a €150 million capital expenditure line earmarked specifically for M&A opportunities. This dedicated fund provides Juvisé with the immediate resources needed to act decisively on acquisition targets that align with its strategy. The confidence shown by a major institutional investor like Hayfin, which has a strong track record in the healthcare sector, serves as a powerful endorsement of Juvisé’s business model and its potential for future value creation.

This financing builds on previous capital rounds, including investments from Bpifrance and Pemberton in 2024, solidifying a financial foundation robust enough to support a sustained campaign of strategic acquisitions. With capital readily available, the new leadership team is well-positioned to accelerate the company’s proven growth-by-acquisition blueprint.

A Proven Blueprint for Revitalizing Medicines

Juvisé's strategy is not speculative; it is based on a well-honed model of identifying, acquiring, and optimizing the commercialization of essential medicines. The company has a history of successfully integrating major products into its portfolio. In March 2024, it acquired the global rights (ex-US and Canada) to the multiple sclerosis drug Ponvory from a Johnson & Johnson subsidiary, significantly bolstering its neurology franchise.

Previously, in 2022, it acquired worldwide rights to Pylera, a key treatment for Helicobacter pylori infections, from AbbVie. An even earlier landmark deal involved the acquisition of the cancer drugs Arimidex and Casodex from AstraZeneca, which marked Juvisé's successful entry into the oncology market. Each acquisition has been carefully integrated using the company's "asset-light" infrastructure, which leverages a network of partners for manufacturing and distribution while maintaining tight strategic control.

A core tenet of this model is the relocation of manufacturing to Europe. The company has set an ambitious goal to have nearly 100% of its production based in Europe to ensure supply chain reliability, uphold stringent quality standards, and contribute to the continent's industrial and health sovereignty. This focus on operational excellence, combined with a sharp eye for undervalued assets, will continue to guide its M&A activities under the new leadership structure.